Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 2Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

pembrolizumab 64Carboplatin 63Paclitaxel 54Magnetic Resonance Spectroscopy 45Specimen Handling 43Cisplatin 43Gemcitabine 35Bevacizumab 31Docetaxel 30Doxorubicin 29Leucovorin 28Fluorouracil 27Dexamethasone 27Cyclophosphamide 26Pemetrexed 25Radiation 23Oxaliplatin 23Radiotherapy 22Etoposide 22durvalumab 21Nivolumab 21Letrozole 21Vincristine 20Rituximab 20Irinotecan 20Taxes 19Prednisone 19Capecitabine 19Lenalidomide 18130-nm albumin-bound paclitaxel 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × pazopanib × 30 days × Clear all
NCT01575548 2026-05-29

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

National Cancer Institute (NCI)

Phase 3 Active not recruiting
129 enrolled 11 charts
Genitourinary

Carcinoma, Renal Cell

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Incyte Corporation

Phase 3 Completed
129 enrolled 13 charts
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡